FNA vs. SIBN, KIDS, OFIX, IRMD, SILK, ATRI, EMBC, BVS, SRDX, and PLSE
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include SI-BONE (SIBN), OrthoPediatrics (KIDS), Orthofix Medical (OFIX), Iradimed (IRMD), Silk Road Medical (SILK), Atrion (ATRI), Embecta (EMBC), Bioventus (BVS), Surmodics (SRDX), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Paragon 28 (NYSE:FNA) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Paragon 28 has a net margin of -24.45% compared to SI-BONE's net margin of -29.93%. SI-BONE's return on equity of -25.14% beat Paragon 28's return on equity.
In the previous week, SI-BONE had 8 more articles in the media than Paragon 28. MarketBeat recorded 11 mentions for SI-BONE and 3 mentions for Paragon 28. SI-BONE's average media sentiment score of 0.45 beat Paragon 28's score of 0.07 indicating that SI-BONE is being referred to more favorably in the news media.
SI-BONE received 131 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 80.56% of users gave Paragon 28 an outperform vote while only 67.23% of users gave SI-BONE an outperform vote.
SI-BONE has lower revenue, but higher earnings than Paragon 28. SI-BONE is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
63.6% of Paragon 28 shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 15.3% of Paragon 28 shares are owned by insiders. Comparatively, 5.4% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Paragon 28 presently has a consensus target price of $16.75, indicating a potential upside of 120.11%. SI-BONE has a consensus target price of $27.29, indicating a potential upside of 84.99%. Given Paragon 28's higher possible upside, analysts clearly believe Paragon 28 is more favorable than SI-BONE.
Paragon 28 has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Summary
SI-BONE beats Paragon 28 on 9 of the 17 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
